CD79b inhib 
Welcome,         Profile    Billing    Logout  
 1 Company  1 Product   1 Product   0 Diseases   3 Trials   11 News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
JNJ-8543 / J&J
NCT06139406: A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer

Recruiting
1
70
Europe, RoW
JNJ-87801493, JNJ-80948543, JNJ-75348780
Janssen Research & Development, LLC
Lymphoma, Non-Hodgkin
07/26
07/26
NCT05424822: A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Recruiting
1
220
Europe, Japan, US, RoW
JNJ-80948543
Janssen Research & Development, LLC
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
06/26
11/26
NCT06660563: A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)

Recruiting
1
40
Europe, RoW
JNJ-80948543, JNJ-75348780
Janssen Research & Development, LLC
Lymphoma, Non-Hodgkin
09/26
09/26
anti-CD79b/CD3 TDB / Roche
No trials found
IBI38D9-L / Innovent Biologics
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
JNJ-8543 / J&J
NCT06139406: A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer

Recruiting
1
70
Europe, RoW
JNJ-87801493, JNJ-80948543, JNJ-75348780
Janssen Research & Development, LLC
Lymphoma, Non-Hodgkin
07/26
07/26
NCT05424822: A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Recruiting
1
220
Europe, Japan, US, RoW
JNJ-80948543
Janssen Research & Development, LLC
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
06/26
11/26
NCT06660563: A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)

Recruiting
1
40
Europe, RoW
JNJ-80948543, JNJ-75348780
Janssen Research & Development, LLC
Lymphoma, Non-Hodgkin
09/26
09/26
anti-CD79b/CD3 TDB / Roche
No trials found
IBI38D9-L / Innovent Biologics
No trials found

Download Options